Log in Free sign up

AC Immune (ACIU) News and press releases

News

From Benzinga Pro

Stocks That Hit 52-Week Lows On Wednesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Wednesday, 807 companies reached new 52-week lows.

AC Immune Reports Its Anti-Abeta Vaccine Results From Phase 1b Study In Down Syndrome Were Published In 'JAMA Neurology'

Biotech, News, FDA, General

First study of an anti-Abeta vaccine in people living with Down syndrome (DS) Immune response and Alzheimer’s disease (AD) biomarkers showed positive impact of ACI-24 first generation vaccine Optimized

Stocks That Hit 52-Week Lows On Friday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Friday, 1043 companies hit new 52-week lows.

Stocks That Hit 52-Week Lows On Thursday

News, Options, Intraday Update, Markets

During Thursday, 849 stocks hit new 52-week lows.

Recap: AC Immune Q1 Earnings

AC Immune (NASDAQ:ACIU) reported its Q1 earnings results on Thursday, April 28, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

AC Immune Says KOL Webinar On First Clinical Proof Of Concept For Alpha-Synuclein Diagnostic Shows Breakthrough Potential For Neurodegenerative Diseases

News, FDA, Events

AC Immune KOL Webinar on First Clinical Proof of Concept for Alpha-synuclein Diagnostic Shows Breakthrough Potential for Neurodegenerative diseases a-syn PET tracer, ACI-12589, clinically validated in MSA, potentially

AC Immune: Q4 Earnings Insights

AC Immune (NASDAQ:ACIU) reported its Q4 earnings results on Tuesday, March 22, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Earnings AC Immune reported an EPS of $-0.28.

AC Immune Reports FY21 Cash Balance Of CHF198.2M

Analysis of Financial Statements for the year ended December 31, 2021 Cash Position: The Company had a total cash balance of CHF 198.2 million, composed of CHF 82.2 million in cash and cash equivalents and CHF

The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill

Biotech, News, Penny Stocks, Small Cap, FDA, Top Stories, General

Here's a roundup of top developments in the biotech space over the last 24 hours.

AC Immune Reports First Live Images Of Alpha-Synuclein In Human Brain With New PET Tracer For Neurodegenerative Disease At AD/PDTM Conference

ACI-12589 distinguished multiple system atrophy (MSA) from other a-synucleinopathies and healthy volunteers A-syn PET tracers may be developed to diagnose a-synuclein pathologies, including Parkinson's

The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings

Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, Top Stories, General

Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week.

Stocks That Hit 52-Week Lows On Monday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Monday, 524 stocks hit new 52-week lows.

AC Immune-Janssen Partnered Alzheimer's Vaccine Shows Tau-Specific Antibodies In Early-Stage Trial

Biotech, News, Penny Stocks, Health Care, Small Cap, Movers, Trading Ideas, General

AC Immune SA (NASDAQ: ACIU) and partner Janssen, a unit of Johnson & Johnson (NYSE: JNJ), have found that an early-stage Alzheimer's vaccine spurs induction of antibodies that attack a type of tau, a

AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety And Potent Immunogenicity Of pTau Alzheimer's Vaccine In High-dose Cohort

Biotech, News, FDA, General

AC Immune SA (NASDAQ:ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced new interim 10-week data from the high-dose cohort of a

Press releases

From Benzinga Pro

AC Immune's Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology

Health Care, Press Releases

First study of an anti-Abeta vaccine in people living with Down syndrome (DS) Immune response and Alzheimer's disease (AD) biomarkers showed positive impact of ACI-24 first generation vaccine Optimized formulation of

AC Immune Reports First Quarter 2022 Financial Results and Provides Corporate Update

Earnings, Press Releases

Two clinical readouts delivered in Q1; five more expected by year-end Interim data from the Phase 1b/2a trial of ACI-35.030 confirm the favorable safety and potent immunogenicity of this first-in-class anti-pTau

AC Immune to Present at the B. Riley Annual Neuro & Ophthalmology Virtual Investor Conference

News, Press Releases

LAUSANNE, Switzerland, April 27, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that

AC Immune Reports Changes to Senior Management

News, Management, Press Releases

Howard Donovan appointed Chief HR Officer, joins executive committee Joerg Hornstein, CFO, will leave to pursue new role Chris Roberts promoted to Vice President, Finance and appointed Interim CFO Julian Snow promoted

AC Immune KOL Webinar on First Clinical Proof of Concept for Alpha-synuclein Diagnostic Shows Breakthrough Potential for Neurodegenerative diseases

Health Care, Press Releases

a-syn PET tracer, ACI-12589, clinically validated in MSA, potentially enables accelerated development of targeted therapeutics and additional a-syn diagnostics Another first for validated Morphomer® discovery

AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update

Earnings, Press Releases

Seven clinical data readouts expected in 2022Three vaccines, targeting Tau, Abeta and alpha-synuclein, advancing in 2022Semorinemab Phase 2 Lauriet trial: additional fluid biomarker data expected in H2 2022Initiation of

AC Immune to Host Key Opinion Leader Webinar on Alpha-Synuclein as a Target in Neurodegenerative Diseases

Health Care, Press Releases

LAUSANNE, Switzerland, March 21, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, will host a key

AC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurodegenerative Disease at AD/PDTM Conference

Health Care, Press Releases

ACI-12589 distinguished multiple system atrophy (MSA) from other a-synucleinopathies and healthy volunteers A-syn PET tracers may be developed to diagnose a-synuclein pathologies, including Parkinson's disease, Lewy

AC Immune to Present at the AD/PD™ 2022 New Clinical and Preclinical Data for Alpha-Synuclein, Abeta and TDP-43 Programs

News, Health Care, Press Releases

Five presentations at the International Conference on Alzheimer's & Parkinson's Diseases (AD/PDTM) AC Immune's Chief Medical Officer to participate in expert forum on translational drug discovery for

AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer's Vaccine in High-dose Cohort

Health Care, Analyst Ratings, Press Releases

Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment ACI-35.030 continues to be well tolerated with no clinically relevant safety concerns observed in low-, mid- or